Skip to content

Novel MRI Techniques in the Evaluation of Pulmonary Vascular Disease

Novel MRI Techniques in the Evaluation of Pulmonary Vascular Disease

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02026531
Enrollment
9
Registered
2014-01-03
Start date
2010-11-30
Completion date
2015-09-30
Last updated
2015-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Brief summary

The diagnosis of a patient with pulmonary hypertension (PH) requires many investigations. At present cardiac catheterisation is the cornerstone investigation in these patients where it is used to establish disease severity and estimate prognosis. It is an invasive procedure which is expensive and not without risk to the patient. Despite the multitude of tests performed, identifying those patients with PH who have a poor diagnosis can be difficult. The aim of this study is to improve the assessment of patients with PH using novel magnetic resonance techniques.

Interventions

OTHER3-Helium gas

3-Helium gas for MRI contrast

Sponsors

University of Sheffield
CollaboratorOTHER
Sheffield Teaching Hospitals NHS Foundation Trust
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* All cases referred to the clinic for assessment for possible pulmonary hypertension.

Exclusion criteria

* patients with a cardiac pacemaker or retained temporary pacing wire * patients with aneurysm clip * non MRI compatible heart valve prosthesis * intra orbital metalic foreign body * pregnancy * metal prosthesis/spinal rods * retained shrapnel * cochlear implants/bladder stimulator

Design outcomes

Primary

MeasureTime frameDescription
pulmonary artery diameter (mm)up to 3 monthsThree-dimensional MRI imaging will be used to acquire cardiac dimensions and anatomical ventilation distribution as well as regional partial pressures of oxygen in the lungs.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026